Incyte Genomics Inc (INCY) — Analysis Summary
Incyte Genomics Inc (INCY) has a market cap of $19.33B with year-over-year revenue growth of +21.2%. Net margin stands at 25.0%. The stock trades at a P/E ratio of 13.5.
Key Takeaways
- Revenue changed +21.2% year-over-year
- Net margin of 25.0%
- P/E ratio of 13.5
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, INCY posted revenue growth of +21.2% and trades at a P/E of 13.5.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.